Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)
Study of ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)
ClinicalTrials.gov ID: NCT06291376
Sponsor: Alexion Pharmaceuticals, Inc.
Information provided by: Alexion Pharmaceuticals, Inc. (Responsible Party)
Last Update Posted: 2024-07-31
Brief Summary:
The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.
Detailed Description:
The I CAN study will enroll approximately 450 eligible participants with IgAN who are high risk of disease progression. Participants will be on stable concomitant IgAN treatment(s) consistent with standard of care for patients with IgAN for at least 3 months prior to Screening, Participants will be randomized in a 1:1 allocation ratio to receive a weight-based IV infusion of either ravulizumab or placebo. An interim analysis may be conducted at Week 34 to evaluate change in proteinuria and the final analysis will be conducted at Week 106 to evaluate eGFR. In addition, approximately 20 participants with eGFR 20-29 mL/min/1.73m2 will be enrolled in an Exploratory Cohort and will receive open label weight-based IV infusion of ravulizumab. After Week 106, all participants have the option to enter a post-study access period and receive open-label ravulizumab.
Official Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)
Intervention / Treatment:
- Drug: Ravulizumab
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) |
2024-03-29
|
| Primary Completion (Estimated) |
2026-02-23
|
| Study Completion (Estimated) |
2029-10-25
|
| Enrollment (Estimated) | 470 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
D928FC00001
|